Literature DB >> 28964807

Protective effects of resveratrol on mitochondrial function in the hippocampus improves inflammation-induced depressive-like behavior.

Wen-Jin Chen1, Jian-Kui Du2, Xing Hu2, Qing Yu2, Dong-Xia Li3, Chang-Nan Wang2, Xiao-Yan Zhu4, Yu-Jian Liu5.   

Abstract

Growing evidence suggests that inflammatory processes may be involved in depressive disorders. Inflammation is known to induce mitochondrial dysfunction in the nervous system. However, whether mitochondrial dysfunction is involved in the occurrence of inflammation-induced depressive-like behavior remains to be investigated. The present study aims to firstly, clarify whether mitochondrial dysfunction contributes to lipopolysaccharide (LPS)-induced depression-like behavior in mice and secondly, determine whether the anti-oxidant resveratrol alleviates inflammation-induced depressive-like behavior through the prevention of mitochondrial dysfunction in the hippocampus. We found that the administration of LPS led to mitochondrial oxidative stress and dysfunction as evidenced by increased mitochondrial superoxide production and decreased mitochondrial membrane potential and ATP production in the hippocampus. These effects were attenuated by intracerebroventricular (ICV) Injection of the mitochondria-targeted antioxidant Mito-TEMPO. LPS-treated mice displayed depressive-like behaviors as evidenced by reduced sucrose preference, increased immobility time and decreased struggling time in the forced swimming test. Both Mito-TEMPO and resveratrol could significantly improve the LPS-induced depressive-like behaviors. In contrast, ICV Injection of rotenone, the mitochondrial respiratory chain inhibitor, induced mitochondrial oxidative stress and dysfunction in the hippocampus, and resulted in depressive-like behaviors. Moreover, resveratrol alleviated the LPS-induced apoptosis of hippocampal cells. The antidepressant action of resveratrol was accomplished through the interruption of mitochondrial oxidative stress and the prevention of cell apoptosis in the hippocampus. These findings support the potential for resveratrol as a possible pharmacological agent for depression treatment in the future.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Depression-like behavior; Hippocampus; Lipopolysaccharide; Mitochondrial dysfunction; Resveratrol

Mesh:

Substances:

Year:  2017        PMID: 28964807     DOI: 10.1016/j.physbeh.2017.09.024

Source DB:  PubMed          Journal:  Physiol Behav        ISSN: 0031-9384


  19 in total

Review 1.  Advances in understanding mechanisms and therapeutic targets to treat comorbid depression and cardiovascular disease.

Authors:  Brittany S Pope; Susan K Wood
Journal:  Neurosci Biobehav Rev       Date:  2020-06-26       Impact factor: 8.989

2.  Deletion of Crtc1 leads to hippocampal neuroenergetic impairments associated with depressive-like behavior.

Authors:  Antoine Cherix; Carole Poitry-Yamate; Bernard Lanz; Olivia Zanoletti; Jocelyn Grosse; Carmen Sandi; Rolf Gruetter; Jean-René Cardinaux
Journal:  Mol Psychiatry       Date:  2022-10-12       Impact factor: 13.437

3.  Effect of Season of Birth on Hippocampus Volume in a Transdiagnostic Sample of Patients With Depression and Schizophrenia.

Authors:  Nora Schaub; Nina Ammann; Frauke Conring; Thomas Müller; Andrea Federspiel; Roland Wiest; Robert Hoepner; Katharina Stegmayer; Sebastian Walther
Journal:  Front Hum Neurosci       Date:  2022-06-13       Impact factor: 3.473

4.  Resveratrol ameliorates estrogen deficiency-induced depression- and anxiety-like behaviors and hippocampal inflammation in mice.

Authors:  Tianyao Liu; Yuanyuan Ma; Ruiyu Zhang; Hongyu Zhong; Lian Wang; Jinghui Zhao; Ling Yang; Xiaotang Fan
Journal:  Psychopharmacology (Berl)       Date:  2019-01-04       Impact factor: 4.530

5.  Lipopolysaccharide induces human olfactory ensheathing glial apoptosis by promoting mitochondrial dysfunction and activating the JNK-Bnip3-Bax pathway.

Authors:  Maowei He; Zimin Xiang; Libin Xu; Yanting Duan; Fangqin Li; Jianmei Chen
Journal:  Cell Stress Chaperones       Date:  2018-10-29       Impact factor: 3.667

Review 6.  Mitochondria and Mood: Mitochondrial Dysfunction as a Key Player in the Manifestation of Depression.

Authors:  Josh Allen; Raquel Romay-Tallon; Kyle J Brymer; Hector J Caruncho; Lisa E Kalynchuk
Journal:  Front Neurosci       Date:  2018-06-06       Impact factor: 4.677

Review 7.  Resveratrol and Depression in Animal Models: A Systematic Review of the Biological Mechanisms.

Authors:  Alyssa Moore; Joshua Beidler; Mee Young Hong
Journal:  Molecules       Date:  2018-08-30       Impact factor: 4.411

8.  Modulation of fat metabolism and gut microbiota by resveratrol on high-fat diet-induced obese mice.

Authors:  C Linda Campbell; Renqiang Yu; Fengzhi Li; Qin Zhou; Daozhen Chen; Ce Qi; Yongxiang Yin; Jin Sun
Journal:  Diabetes Metab Syndr Obes       Date:  2019-01-04       Impact factor: 3.168

9.  Inhibition of Phosphodiesterase 4 by FCPR03 Alleviates Lipopolysaccharide-Induced Depressive-Like Behaviors in Mice: Involvement of p38 and JNK Signaling Pathways.

Authors:  Hui Yu; Zhengqiang Zou; Xiaolin Zhang; Wanli Peng; Chen Chen; Yicheng Ye; Jiangping Xu; Haitao Wang
Journal:  Int J Mol Sci       Date:  2018-02-08       Impact factor: 5.923

10.  E-Configuration Improves Antioxidant and Cytoprotective Capacities of Resveratrols.

Authors:  Jian Lin; Xican Li; Ban Chen; Gang Wei; Dongfeng Chen
Journal:  Molecules       Date:  2018-07-20       Impact factor: 4.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.